Smith & Nephew Share Chat (SN.)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Smith & Nephew	LSE:SN.	London	Ordinary Share	GB0009223206	ORD USD0.20

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-9.00p	-0.67%	1,325.00p	1,325.00p	1,326.00p	1,338.00p	1,322.00p	1,335.00p	1,581,925	16:35:16

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	3,781.0	860.0	71.3	19.5	11,595.30

Smith & Nephew Share Discussion Threads

Showing 776 to 800 of 800 messages

Chat Pages: 32 31 30 29 28 27 26 25 24 23 22 21 Older

Date	Subject	Author	Discuss
25/5/2017 10:06	New all time highs on an almost daily basis. And not a whisper in the press ...	mamcw	Read Full Thread Reply
05/5/2017 09:35	Smith & Nephew said its full year outlook for underlying revenue growth remained unchanged in the 3%-4% range after posting flat first quarter revenue of $1.14bn, flat on a reported basis after -2% impact from the disposal of its gynaecology business and -1% currency headwind. Revenue was up 3% on an underlying basis for the period. Established markets, the US and other established markets revenue were all up 1%. "In Europe we are making progress improving our execution, although the slight headwinds seen last year in some European countries continued,"Smith & Nephew said. "Performance in the emerging markets was good, returning to double-digit growth, with China growing 14% in the quarter." "On a reported basis, we expect 2017 revenue growth to be in the range of 1.6%-2.6% based on prevailing exchange rates at the end of April and reflecting the 80bps headwind from the disposal of the gynaecology business," the company said.	broadwood	Read Full Thread Reply
05/5/2017 07:26	Live bid candidate. - Smith & Nephew said its Q1 2017 trading was in line with its expectations, and that it was on track to deliver 3-4% underlying revenue growth for the FY. CEO Olivier Bohuon said that in particular the company's performance in the Emerging Markets was good, returning to double-digit growth, with China up 14% underlying. "Our innovative new products, such as the Lens camera and Werewolf Coblation systems, have been well received, and we look forward to the imminent full market release of the Total Knee Application on our Navio robotics-assisted surgery system," said Bohuon. "Over the last few years we have successfully put in place the right structures and capabilities to make the Group stronger, simpler, more agile and efficient. "We continue to focus on execution and expect to see progress through the year." Meantime, for Q1, revenue of $1.142bn was flat on a reported basis after -2% impact from Gynaecology disposal and -1% currency headwind. It was up 3% on an underlying basis. "Smith & Nephew is on-track to deliver 3-4% underlying revenue growth for full year," it said.	broadwood	Read Full Thread Reply
10/3/2017 09:49	Now Akzo Nobel falls under the global consolidation hammer. Only a matter of time before SN is bought	mamcw	Read Full Thread Reply
21/2/2017 15:42	Unilever situation underlines attractiveness of UK-based companies whose earnings are global to US predators.	mamcw	Read Full Thread Reply
09/2/2017 18:58	Nice come back today. Forming a long lower wick to daily candle.	corlis	Read Full Thread Reply
09/2/2017 17:51	sharp dip at the open but regained nearly all losses to close at 1198. it appears that someone is very keen to accumulate loose stock.	accipitridae	Read Full Thread Reply
09/2/2017 09:37	dont forget results reflect a period when the CEO took time out for illness and also lost his CFO. SN generates loads of cash and margins are going up now.	accipitridae	Read Full Thread Reply
09/2/2017 08:38	And down we go on a pretty lacklustre set of results.Doesn't look like we're going to see a marked acceleration in growth in 2017 given a forecast of revenue growth of around 2% and margins,whilst improving,being subject to various "headwinds"."Stryke(r) while the iron's hot" as they say and if they are to rebid,now is a opportune time when the dollar is strong and S&N have undertaken a lot of remedial action.For now,bid expectations will restrict the downside.Along with Astra Zeneca,S&N remains a slow burning fuse that has still to convince the market of its ability to resume a much improved and sustainable growth pattern.I can't help thinking though that global demographics dictates that this company must be very attractive to predators.So,I remain a strong holder.Either they get their act together or get taken over.	steeplejack	Read Full Thread Reply
08/2/2017 22:07	ok i buy any dips	accipitridae	Read Full Thread Reply
08/2/2017 10:56	Accipitidae sorry i meant for a LONG	corlis	Read Full Thread Reply
08/2/2017 08:52	exactly 1200 - what does this mean	accipitridae	Read Full Thread Reply
06/2/2017 09:24	Chart wise this at 1,200 is starting to show some promise.	corlis	Read Full Thread Reply
01/2/2017 12:32	This looks like a fairly straightforward f/x play - with so much of S&N's sales worldwide, yet a stock market valuation that in US Dollar terms has fallen sharply, it becomes very affordable to a US based purchaser.	mamcw	Read Full Thread Reply
26/1/2017 18:21	dont recall ever seeing a company before that is 10% below its all time highs but is actually a dog. it is a dog because it has under-performed its closest peer by 50% and look at it in dollar terms, it is 30% down over 2.5 years.	accipitridae	Read Full Thread Reply
26/1/2017 15:48	what is the management doing about it?	accipitridae	Read Full Thread Reply
26/1/2017 15:47	underperformed its key competitor by nearly 50%. that makes this stock a dog and therefore a good reason it should be sold.	accipitridae	Read Full Thread Reply
26/1/2017 11:43	now J&J is tied up with Actelion could Stryker finally move on S&N ? Stryker could take advantage of the current price disparity in charts above to get S&N at bargain price. J&J Seals $30 Billion Actelion Deal in Push for Rare Disease https://www.bloomberg.com/news/articles/2017-01-26/j-jto-buy-actelion-for-30-billion-spin-off-research-operations	accipitridae	Read Full Thread Reply
25/1/2017 17:08	but i cannot work out why. any explanations welcomed!	accipitridae	Read Full Thread Reply
25/1/2017 17:06	nearly 50% under-performance by S&N since the beginning of last year	accipitridae	Read Full Thread Reply
17/1/2017 08:48	ADRs surged overnight, worth about £12.64	accipitridae	Read Full Thread Reply
22/12/2016 09:56	looks like J&J might get Actelion after all. perhaps that will enable stryker to finally make a move here? stryker has outperformed S&N by nearly 50% YTD so it could make use of its more expensive equity.	accipitridae	Read Full Thread Reply
16/12/2016 15:16	could J&J turn in this direction if Actelion goes to Sanofi?	accipitridae	Read Full Thread Reply
26/11/2016 09:06	Get hip to Smith & Nephew's investment appeal, Goldman advises Share 10:36 25 Nov 2016 The hip and joint replacement specialist trades at a discount to sector peer Stryker Goldman Sachs has lowered its earnings estimates for Smith & Nephew PLC (LON:SN. but still rates the medical technology company’s shares a ‘buy’. The estimate changes follow the third quarter trading update earlier this morning and recent exchange rate movements, and see this year’s earnings per share (EPS) forecast decline 3%, while EPS estimates for the next three years have been shaved by 8%, reflecting weaker growth patterns in the third quarter. “While organic revenue growth this year has fallen short of our expectations (we now expect Smith & Nephew to deliver 1.9% organic revenue growth in 2016, down from the 5% that we had forecast at the beginning of 2016, with the slowdown driven largely by China and the Middle East), we continue to believe that SN.L will accelerate organic revenue growth into the 4%-5% range in 2017 and beyond, given its geographic and product mix (>50% of revenues is in higher-growth markets) and a number of upcoming product launches (Renasys Touch and Connect, Navio in total knee, revision hip, and WereWolf),” the heavyweight US investment bank said. The next catalyst for the share price is likely to be the appointment of a chief financial officer, expected before the end of the year. Goldman’s lowered its price target to 1,310p from 1,370p, on the assumption that Smith & Nephew will trade around 18 times projected EPS for 2018; it currently trades at 15.4 times 2018 EPS, whereas sector peer Stryker Corporation (NYSE:SYK) trades on an earnings multiple of 17.4, despite a comparable growth outlook. Goldman deems the disparity as unwarranted, and in fact suggests S&N should trade at a premium to Stryker, thanks to the possibility of being taken out by a competitor.	accipitridae	Read Full Thread Reply
23/11/2016 11:51	could be massive bargin sub £11. underperformed Stryker 45% YTD. is this crazy?	accipitridae	Read Full Thread Reply

Chat Pages: 32 31 30 29 28 27 26 25 24 23 22 21 Older